昂利康: 股票交易异常波动公告

Group 1 - The stock of Zhejiang Anglikang Pharmaceutical Co., Ltd. (stock code: 002940) experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days (June 6, 2025, and June 9, 2025) [1] - The company's board of directors conducted an investigation into the abnormal trading situation and confirmed that there were no undisclosed significant information or major changes affecting the company [1][2] - The only ongoing project is ALK-N001, which received clinical trial approval in April 2025 and is currently in Phase I clinical trials, highlighting the long cycle, high investment, and uncertainty associated with innovative drug development [1][2] Group 2 - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange listing rules, nor any significant information that could impact the stock price [2] - The company emphasizes the importance of rational decision-making for investors, given the inherent risks in the long and costly drug development process [2]